KAYAK THERAPEUTICS ANNOUNCES IND CLEARANCE FOR KT-300, A POTENTIAL FIRST-IN-CLASS TRIM7 INHIBITOR FOR RAS-DRIVEN CANCERS

Reuters · 5d ago

Please log in to view news